U.S. Hemophilia Treatment Market 規模およびシェア分析 - 成長トレンドおよび予測 (2024 - 2031)
U.S. Hemophilia Treatment Market is Segmented By Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Others), By Disease Type (Hemophilia A, Hemophilia B, and Hemophilia C), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). The report offers the value (in USD billion) for the above-mentioned segments.
Competitive overview of U.S. Hemophilia Treatment Market
米国のhemophiliaの処置の市場で作動する主要なプレーヤーはタケダの薬剤 Company Limitedを含んでいます、 サンオフィ Octapharma AG、スウェーデン Orphan Biovitrum AB、Baxter International Inc.、Biogen Inc.、Bayer AG、CSL Behring、フェリングB.V、Pfizer、Inc.、Kedrion、Novo Nordisk A/S、Grifols S.A.、Sangamo Therapeutics、Inc.、Spark Therapeutics、Inc.
U.S. Hemophilia Treatment Market Leaders
- 武田薬品 会社概要
- サンオフィオクタファーマAG
- スウェーデンのOrphan Biovitrum AB
- バクスターインターナショナル 代表取締役
- バイオジェン株式会社
*Disclaimer: Major players are listed in no particular order.
U.S. Hemophilia Treatment Market - Competitive Rivalry, 2023
U.S. Hemophilia Treatment Market
Market Consolidated
(Dominated by major players)
(Dominated by major players)
Market Fragmented
(Highly competitive with lots of players.)
(Highly competitive with lots of players.)
*Source: Coherent Market Insights